|
|
NCCN 4th Annual Congress: Hematologic Malignancies
Select presentations from an educational program held in New York, New York on September 11-12, 2009
Presenters
CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Developments in the Management and Treatment of CLL
Susan O'Brien, MD
The University of Texas M. D. Anderson Cancer Center
Houston, Texas
MULTIPLE MYELOMA
Promising New Agents in the Management of Multiple Myeloma
Adam D. Cohen, MD
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Combination Regimens for First-Line and Salvage Therapy in Multiple Myeloma
Seema Singhal, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois
NON-HODGKIN’S LYMPHOMA (NHL)
Diagnosis of NHL
Nancy Lee Harris, MD
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
The Role of Prognostic Markers in Diffuse Large B-Cell Lymphomas (DLBCL)
Andrew D. Zelenetz, MD, PhD
Memorial Sloan-Kettering Cancer Center
New York, New York
SUPPORTIVE CARE
Management of Tumor Lysis Syndrome
Myron S. Czuczman, MD
Roswell Park Cancer Institute
Buffalo, New York
Platelet Support in the Management of Hematologic Malignancies
David J. Kuter, MD, DPhil
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Controversies in the Management of Anemia
Eric H. Kraut, MD
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
Columbus, Ohio
Iron Supplementation in Patients with Cancer
Stephen D. Nimer, MD
Memorial Sloan-Kettering Cancer Center
New York, New York
Program Overview
The treatment of hematologic malignancies is increasingly complex. Issues relating to pathology, transplantation, and various new therapies require oncologists and hematologists to stay abreast of new advances. In addition, targeted therapies and oral treatments bring new benefits to patients. This activity will focus on the new approaches that have been incorporated into patient management, including the use of drugs, biologics, and diagnostics. Chronic lymphocytic leukemia, multiple myeloma, non-Hodgkin’s lymphomas, and supportive care issues in hematologic malignancies will be addressed.
Educational Objectives
Following this activity, participants should be able to:
Developments in the Management and Treatment of CLL- State the various treatment options available for the management of patients with untreated and relapsed or refractory CLL
Promising New Agents in the Management of Multiple Myeloma- Review the clinical results of investigational agents for the treatment of multiple myeloma
Combination Regimens for First Line and Salvage Therapy in Multiple Myeloma- Identify optimal induction therapies for patients with newly diagnosed multiple myeloma
- List clinical studies relating to the treatment of relapsed multiple myeloma in elderly patients
Diagnosis of NHL- Summarize some of the significant changes incorporated in the recently updated 2008 World Health Organization (WHO) classification of lymphomas
The Role of Prognostic Markers in Diffuse Large B-Cell Lymphomas- Identify the prognostic significance of biomarkers and the role of gene expression profiling in DLBCL
Management of Tumor Lysis Syndrome- Describe the characteristics and management strategies of tumor lysis syndrome, a potentially fatal complication in hematological malignancies
Platelet Support in the Management of Hematologic Malignancies- Summarize the role of platelet growth-promoting agents in the management of thrombocytopenia
Controversies in the Management of Anemia- Outline the risks and benefits of erythropoiesis-stimulating agents (ESAs) and blood transfusions in the management of anemia in cancer patients
Iron Supplementation in Patients with Cancer- Outline the clinical evidence demonstrating the value of intravenous iron supplementation in ESA therapy for patients with chemotherapy-induced anemia
Intended Audience
This educational activity is designed to meet the needs of physicians, nurses, and other clinical professionals who manage patients with cancer.
Activity Instructions
This activity is composed of nine separate presentations. Continuing education credit will be awarded based on the number of presentations viewed and post-tests passed with a score of 80% or higher. Participants should review the learning objectives and faculty disclosure statements prior to viewing and listening to a presentation in its entirety. You must be connected to the Internet in order to review and complete the post-test and the evaluation form. A statement of credit will be electronically generated once you pass the post-test and complete the evaluation form. To receive credit, this activity must be completed no later than November 18, 2010. There is no fee for participating in this activity.
Accreditation Information
Physicians
The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.
NCCN designates this educational activity for a maximum of 5.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Partial credit may be awarded as follows:
Developments in the Management and Treatment of CLL – 0.5 AMA PRA Category 1 Credit(s)™
Promising New Agents in the Management of Multiple Myeloma – 0.75 AMA PRA Category 1 Credit(s)™
Combination Regimens for First Line and Salvage Therapy in Multiple Myeloma – 0.5 AMA PRA Category 1 Credit(s)™
Diagnosis of NHL – 0.75 AMA PRA Category 1 Credit(s)™
The Role of Prognostic Markers in Diffuse Large B-Cell Lymphomas – 0.75 AMA PRA Category 1 Credit(s)™
Management of Tumor Lysis Syndrome – 0.5 AMA PRA Category 1 Credit(s)™
Platelet Support in the Management of Hematologic Malignancies – 0.75 AMA PRA Category 1 Credit(s)™
Controversies in the Management of Anemia – 0.5 AMA PRA Category 1 Credit(s)™
Iron Supplementation in Patients with Cancer – 0.75 AMA PRA Category 1 Credit(s)™
Nurses
This activity is approved for 5.8 contact hours. National Comprehensive Cancer Network is an approved provider of continuing nursing education by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
Partial credit may be awarded as follows:
Developments in the Management and Treatment of CLL – 0.6 contact hours
Promising New Agents in the Management of Multiple Myeloma – 0.7 contact hours
Combination Regimens for First Line and Salvage Therapy in Multiple Myeloma – 0.6 contact hours
Diagnosis of NHL – 0.7 contact hours
The Role of Prognostic Markers in Diffuse Large B-Cell Lymphomas – 0.7 contact hours
Management of Tumor Lysis Syndrome – 0.5 contact hours
Platelet Support in the Management of Hematologic Malignancies – 0.8 contact hours
Controversies in the Management of Anemia – 0.5 contact hours
Iron Supplementation in Patients with Cancer – 0.7 contact hours
Approval as a provider refers to recognition of educational activities only and does not imply ANCC Commission on Accreditation or PA Nurses approval or endorsement of any product.
Kristina M. Gregory, RN, MSN,OCN, is our nurse planner for this educational activity.
Release date: November 18, 2009
Expiration date: November 18, 2010
Commercial Support
Supported by educational grants from Allos Therapeutics, Inc, Amgen, Centocor Ortho Biotech Services LLC, Genentech BioOncology and Biogen Idec, and Millennium Pharmaceuticals, Inc.
|
